Conditions: KRAS-mutant Non-small Cell Lung Cancer (NSCLC); KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC); KRAS-mutant Colorectal Cancer (CRC); Other KRAS-mutant Solid Tumors
Interventions: Drug: KST-6051
Sponsors: Kestrel Therapeutics, Inc.
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
